Berkan Kurt, MD
@berkankurt.bsky.social
MD | Cardiology Resident | RWTH Aachen | Clinician Scientist @Kahles Lab | #Inflammation, #immunocardiology and #cardiometabolic disease | #CardioSky
Our article “C-reactive protein and cardiovascular risk in the general population” is now published in the European Heart Journal.
Open Access: academic.oup.com/eurheartj/ad...
@escardio.bsky.social @dgk-org.bsky.social
Open Access: academic.oup.com/eurheartj/ad...
@escardio.bsky.social @dgk-org.bsky.social
December 11, 2025 at 5:41 PM
Our article “C-reactive protein and cardiovascular risk in the general population” is now published in the European Heart Journal.
Open Access: academic.oup.com/eurheartj/ad...
@escardio.bsky.social @dgk-org.bsky.social
Open Access: academic.oup.com/eurheartj/ad...
@escardio.bsky.social @dgk-org.bsky.social
🫀 Out now: In our new review, we look at heart failure with a focus on chronic low-grade inflammation, discuss how hsCRP, IL-6 and other biomarkers capture residual inflammatory risk in HFpEF and HFrEF and may help guide future anti-inflammatory strategies. 🔥 💉
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates - Current Heart Failure Reports
Purpose of Review Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Increasing evidence highlights that systemic low-grade inflammation is a key pathophysiological drive...
link.springer.com
November 8, 2025 at 1:28 PM
🫀 Out now: In our new review, we look at heart failure with a focus on chronic low-grade inflammation, discuss how hsCRP, IL-6 and other biomarkers capture residual inflammatory risk in HFpEF and HFrEF and may help guide future anti-inflammatory strategies. 🔥 💉
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Excited to share our new paper is now out in #Atherosclerosis:
In patients with #ASCVD, adding #bioADM to the ESC-recommended #SMART risk score improves risk prediction and model performance.
Thanks to all collaborators for the joint effort.
Read here (open access): tinyurl.com/3jtdhpzv
In patients with #ASCVD, adding #bioADM to the ESC-recommended #SMART risk score improves risk prediction and model performance.
Thanks to all collaborators for the joint effort.
Read here (open access): tinyurl.com/3jtdhpzv
Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD
Bioactive adrenomedullin 1-52 (bio-ADM) is a novel biomarker for the assessment of
endothelial function and prediction of adverse outcomes in patients with acute heart
failure and cardiogenic shock. T...
tinyurl.com
May 30, 2025 at 8:50 AM
Excited to share our new paper is now out in #Atherosclerosis:
In patients with #ASCVD, adding #bioADM to the ESC-recommended #SMART risk score improves risk prediction and model performance.
Thanks to all collaborators for the joint effort.
Read here (open access): tinyurl.com/3jtdhpzv
In patients with #ASCVD, adding #bioADM to the ESC-recommended #SMART risk score improves risk prediction and model performance.
Thanks to all collaborators for the joint effort.
Read here (open access): tinyurl.com/3jtdhpzv